Telavancin is an investigational, rapidly bactericidal
lipoglycopeptide antibiotic that is being developed to treat serious
infections caused by gram-positive bacteria. A baseline prospective surveillance study was conducted to assess
telavancin activity, in comparison with other agents, against contemporary clinical isolates collected from 2004 to 2005 from across the United States. Nearly 4,000 isolates were collected, including staphylococci, enterococci, and streptococci (pneumococci, beta-hemolytic, and viridans).
Telavancin had potent activity against Staphylococcus aureus and
coagulase-negative staphylococci (MIC range, 0.03 to 1.0 microg/ml), independent of resistance to
methicillin or to multiple agents.
Telavancin activity was particularly potent against all streptococcal groups (MIC(90)s, 0.03 to 0.12 microg/ml).
Telavancin had excellent activity against
vancomycin-susceptible enterococci (MIC(90), 1 microg/ml) and was active against VanB strains of vancomycin-resistant enterococci (MIC(90), 2 microg/ml) but less active against VanA strains (MIC(90), 8 to 16 microg/ml).
Telavancin also demonstrated activity against
vancomycin-intermediate S. aureus and
vancomycin-resistant S. aureus strains (MICs, 0.5 microg/ml to 1.0 microg/ml and 1.0 microg/ml to 4.0 microg/ml, respectively). These data may support the efficacy of
telavancin for treatment of serious
infections with a wide range of gram-positive organisms.